# A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

> **NCT02018861** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 88 (actual)

## Conditions studied

- B-Cell Malignancies

## Interventions

- **DRUG:** Parsaclisib
- **DRUG:** Itacitinib
- **DRUG:** Rituximab
- **DRUG:** Ifosfamide
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT02018861
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-22
- **Primary completion:** 2021-04-12
- **Final completion:** 2021-04-12
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02018861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02018861, "A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02018861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*